Skip to main content
Por Piklz
Por Piklz

This Whole Deal PikLZ Scientist card collectible featuring Bijijoo art will help offset future early stage innovative research in the Napier Lab.

Dr. Napier's work on the rare disease Blau syndrome caught PikLZ attention for the very first scientist PikLZ card collectibles.

Dr. Napier's lab is focused on understanding the pathogenesis of inflammatory diseases with a hope of identifying drug targets for future therapies. For example, her team is moving us closer to unlocking the role of how the NOD2 gene affects immunity. Because mutations in the NOD2 gene have been shown to track to all sorts of inflammatory syndromes (e.g., Crohn's, psoriatic arthritis, graft vs. host disease, uveitis, rheum arthritis, Yao syndrome, etc.,) supporting her work on the rare disease Blau Syndrome could have additional big impacts on many horrible diseases.

One example to show how funding rare disease research can lead to big solves in many other more prevalent diseases is the rare disease CAPS (Cryopyrin-associated periodic syndrome) Like Blau Syndrome, CAPS is caused by a single DNA mutation. In the case of CAPS the single DNA mutation is in a protein called NLRP3 (a protein similar to NOD2.) Research on CAPS discovered this horrible disease was caused by overproduction of a protein called IL-1b that is important in cell to cell communication. IL-1b was a protein of little interest to the research community at the time. However, after the CAPS research results, scientists quickly developed a drug to target IL-1b. That drug is now used to treat LOTS of horrible diseases (e.g., Gout, rheumatoid arthritis, etc.) that were seemingly unrelated to CAPS.

Let's support Dr. Napier's work by providing the Napier Lab with some early innovation funding that is "stuck in a pickle."

PikLZ - Dr. Ruth Napier Collection collection image

Dr. Napier's work on the rare disease Blau syndrome caught PikLZ attention for the very first scientist PikLZ card collectibles featuring Bijijoo art.

The Napier Lab is focused on understanding the development of inflammatory diseases with a hope of identifying drug targets for future therapies. Her team is moving us closer to unlocking the role of how the NOD2 gene affects immunity. Because mutations in the NOD2 gene have been shown to track to all sorts of inflammatory syndromes (e.g., Crohn's, psoriatic arthritis, graft vs. host disease, uveitis, rheum arthritis, Yao syndrome, etc.,) supporting her work on Blau Syndrome could help develop other inflammatory syndrome treatments.

Let's support Dr. Napier's work by providing some early innovation funding that is "stuck in a pickle."

Dirección del contrato0x495f...7b5e
ID del token
Estándar de tokenERC-1155
CadenaEthereum
MetadatosCentralizado
Ganancias del creador
10%

Whole Deal PikLZ - Dr. Ruth Napier

visibility
27 visualizaciones
  • Precio
    Precio en USD
    Cantidad
    Vencimiento
    De
  • Precio
    Precio en USD
    Cantidad
    Diferencia de suelo
    Vencimiento
    De
keyboard_arrow_down
Evento
Precio
De
Para
Fecha

Whole Deal PikLZ - Dr. Ruth Napier

visibility
27 visualizaciones
  • Precio
    Precio en USD
    Cantidad
    Vencimiento
    De
  • Precio
    Precio en USD
    Cantidad
    Diferencia de suelo
    Vencimiento
    De
Por Piklz
Por Piklz

This Whole Deal PikLZ Scientist card collectible featuring Bijijoo art will help offset future early stage innovative research in the Napier Lab.

Dr. Napier's work on the rare disease Blau syndrome caught PikLZ attention for the very first scientist PikLZ card collectibles.

Dr. Napier's lab is focused on understanding the pathogenesis of inflammatory diseases with a hope of identifying drug targets for future therapies. For example, her team is moving us closer to unlocking the role of how the NOD2 gene affects immunity. Because mutations in the NOD2 gene have been shown to track to all sorts of inflammatory syndromes (e.g., Crohn's, psoriatic arthritis, graft vs. host disease, uveitis, rheum arthritis, Yao syndrome, etc.,) supporting her work on the rare disease Blau Syndrome could have additional big impacts on many horrible diseases.

One example to show how funding rare disease research can lead to big solves in many other more prevalent diseases is the rare disease CAPS (Cryopyrin-associated periodic syndrome) Like Blau Syndrome, CAPS is caused by a single DNA mutation. In the case of CAPS the single DNA mutation is in a protein called NLRP3 (a protein similar to NOD2.) Research on CAPS discovered this horrible disease was caused by overproduction of a protein called IL-1b that is important in cell to cell communication. IL-1b was a protein of little interest to the research community at the time. However, after the CAPS research results, scientists quickly developed a drug to target IL-1b. That drug is now used to treat LOTS of horrible diseases (e.g., Gout, rheumatoid arthritis, etc.) that were seemingly unrelated to CAPS.

Let's support Dr. Napier's work by providing the Napier Lab with some early innovation funding that is "stuck in a pickle."

PikLZ - Dr. Ruth Napier Collection collection image

Dr. Napier's work on the rare disease Blau syndrome caught PikLZ attention for the very first scientist PikLZ card collectibles featuring Bijijoo art.

The Napier Lab is focused on understanding the development of inflammatory diseases with a hope of identifying drug targets for future therapies. Her team is moving us closer to unlocking the role of how the NOD2 gene affects immunity. Because mutations in the NOD2 gene have been shown to track to all sorts of inflammatory syndromes (e.g., Crohn's, psoriatic arthritis, graft vs. host disease, uveitis, rheum arthritis, Yao syndrome, etc.,) supporting her work on Blau Syndrome could help develop other inflammatory syndrome treatments.

Let's support Dr. Napier's work by providing some early innovation funding that is "stuck in a pickle."

Dirección del contrato0x495f...7b5e
ID del token
Estándar de tokenERC-1155
CadenaEthereum
MetadatosCentralizado
Ganancias del creador
10%
keyboard_arrow_down
Evento
Precio
De
Para
Fecha